NowPatient Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 5.3/10
Best for: an oral route if you will not self-inject
NowPatient falls below our bar on disclosure. Read the breakdown below before you give it money.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Covered by the plan
Medication
In the price
Clinician visits
In the price
Shipping
Charged on top
Lab work
Not stated
Coaching
Not stated
Prices checked October 2026
NowPatient, run by Infohealth Ltd with a US office in Austin, gives a free video consultation and sells brand-name weight-loss drugs at published per-dose prices. US orders are dispensed by its pharmacy in Surrey, England, and every price adds shipping and import duties. Delivered, Wegovy tablets start at $119 for 30 days, Foundayo at $133.85, a Wegovy pen at $290.98 and a Mounjaro pen at $326.98, and prices climb with the dose.
Is NowPatient legit?
Yes. NowPatient is a real, operating US company, and we found no FDA warning letters issued to it. We rate it 5.3/10 overall, across six areas from price to trust and safety. Legitimate is not the same as right for you, though: that part is a decision for you and a licensed clinician.
Is there a NowPatient promo or coupon code?
We know of no promo or coupon code for NowPatient. Coupon sites advertising "NowPatient discount codes" are not a source we can vouch for, and any genuine offer shows at checkout without a code.
See how NowPatient compares on our rankings of the best semaglutide providers and the best tirzepatide providers.
Vetted alternatives to NowPatient
Embody
Best for: a flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
Editorial score · methodology
Collective
Best for: flat any-dose pricing, if you can absorb a $199 annual membership on top
Editorial score · methodology
AgelessRx
Best for: microdosed compounded GLP-1s from a longevity clinic, or brand Wegovy at manufacturer pricing plus monitoring
Editorial score · methodology
NowPatient at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Wegovy pill
- Pricing model
- Rises with the dose: higher doses cost more
- What's included
- Medication · Consult
- FDA status
- No FDA warning letters found
How NowPatient scores
Six columns, each one computed from something NowPatient has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where a seller keeps something back, such as its price or its pharmacy, the score reflects it. Every seller we review goes through the same six columns.
Value25%
3.0/10The listed figure is not a comparable monthly price for a named GLP-1 (it may be a membership fee, an insured copay, a per-vial rate or a starting-dose price), so Value is capped rather than scored against other sellers.
Effectiveness25%
10.0/10Dispenses liraglutide, orforglipron, semaglutide and tirzepatide, including the FDA-approved product. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
2.5/10No price appears until the medical intake is finished. A live video visit is required, which is slower but the more careful intake.
Trust & Safety15%
4.0/10No pharmacy is named for its prescriptions. Its price appears only after the medical intake.
Accessibility10%
5.0/10No state list is available to check, so this is held at the midpoint rather than scored on reach.
Support10%
5.5/10The price covers the medication and clinician visits.
A seller that shows no price until after the medical intake loses points on User Experience and Trust & Safety, and its review says so. How we score →
What we checked on NowPatient
Last checked October 2026- Checked the listed price across 5 dose or plan tiers
- Checked what the monthly price covers, and what it leaves out
- Checked FDA warning letters for NowPatient
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below.
What signing up with NowPatient involves
What to expect on the way to a prescription: where the price appears, who fills the medication, and what the monthly price covers. It is not medical advice, and a clinician makes the prescribing decision.
- 1NowPatient shows a price only after you finish its medical questionnaire, so you cannot compare costs until you have shared health information.
- 2The intake requires a live video visit with a clinician before a first prescription, which takes longer than a written form and is the more careful route.
- 3Ask NowPatient which pharmacy fills the prescription before you pay. The pharmacy's name is what lets you check its license.
- 4The monthly price includes the medication and clinician visits.
- Before you commit, get the ongoing monthly price of the medication itself, not a first-month rate, a membership fee or a per-vial price.
- Confirm that NowPatient serves your state before you start.
Contacting NowPatient
- NowPatient offers email support
- Hours
- Mon-Fri 8am-5pm EST (US); Mon-Fri 9am-6pm GMT (UK)
Medications NowPatient lists
NowPatient lists Wegovy, Mounjaro, Foundayo and Saxenda. Each one has its own guide: how it works, the dosing schedule, the side effects that show up in practice, and what the trials measured.
Pricing
Prices re-verified
$99 for the tablets plus a $20 charge for shipping and import duties. Price rises with dose: 4 mg $126, 9 mg $216, 25 mg $279 per 30 tablets, each plus $20.
$113.85 for the tablets plus $20 for shipping and import duties. Price rises with dose: 2.5 and 5.5 mg $158.85, 9 mg $192.60, 14.5 and 17.2 mg $243, each plus $20.
$215.98 per pen plus $75 for shipping and import duties. 1.7 mg $287.98; 2.4 mg and 7.2 mg $395.98 per pen, each plus $75.
$251.98 per pen plus $75 for shipping and import duties, up to $476.98 for 15 mg. In the US, Mounjaro carries a diabetes approval only.
$440.82 for five pens plus $75 for shipping and import duties.
Check the price yourself before you pay
Every figure here comes from NowPatient's own website, as of the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- The monthly price includes the medication and clinician visits
- We found no FDA warning letters issued to NowPatient
- A live video visit with a clinician is required before a prescription, which is slower than a form and is the more careful intake
Against it
- You only see a price after finishing the medical intake, so you cannot compare costs before sharing health information
- Not included in the monthly price: shipping
- Confirm it serves your state before you start the intake
- Ask which pharmacy fills the prescription before you pay, so you can check its license
What NowPatient charges
There is no standard monthly price to quote for NowPatient, so you cannot compare it with other sellers until you have been through an intake and received a quote. When you get one, ask for the ongoing monthly figure and what it includes, not the first-month rate and not a program total divided by its length. NowPatient is not alone in this: about a fifth of GLP-1 sellers publish no price at all.
What NowPatient dispenses
NowPatient prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two molecules with the largest published weight-loss trial programs behind them. These are FDA-approved brand-name products rather than compounded preparations, which is the more expensive route and the one where what is in the pen has been reviewed. Brand names vs molecules sorts out which pen holds which drug. Foundayo is the GLP-1 pill with no fasting rule, approved in April 2026.
Safety and disclosure
Before you start an intake, ask NowPatient which states it serves, which pharmacy fills its prescriptions and what the monthly price includes. We found no FDA warning letters issued to NowPatient. The FDA's warning signs for online medicine sellers are a quick check to run on any seller before you pay. How we weigh oversight, disclosure and price is set out in our scoring methodology.
Who should look elsewhere
- You want to compare prices before spending time on an intake. There is no standard monthly price to compare.
- You need insurance to cover the cost. Check whether NowPatient bills your plan before you start.
Our read
Whether NowPatient is priced well is impossible to judge before an intake, because there is no standard price to compare. That does not rule it out, and plenty of legitimate sellers quote after intake, but it puts the comparison after you have spent the time, which is the wrong order for you as the buyer. WellMedRx is the nearest comparison we review, and worth reading alongside this.
The Bottom Line
NowPatient falls below our bar on disclosure. Read the breakdown below before you give it money.
Before you pay NowPatient
Check today's price, then start the intake.
If you are weighing other sellers, our guide to alternatives to NowPatient sets more sellers in the same category beside NowPatient on price, states and what the price includes.
Frequently Asked Questions
How to check NowPatient yourself
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this NowPatient review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of October 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Aronne LJ et al.)— New England Journal of Medicine.PMID: 40353578.
See NowPatient's current pricing
Whether you qualify is a clinician's decision, made after your intake.